应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AXNX Axonics Inc.
交易中 05-15 15:21:41 EDT
67.71
+0.26
+0.39%
最高
67.75
最低
67.40
成交量
16.40万
今开
67.75
昨收
67.45
日振幅
0.52%
总市值
34.54亿
流通市值
34.16亿
总股本
5,102万
成交额
1,110万
换手率
0.33%
流通股本
5,044万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Needham:重申Axonics(AXNX.US)持有评级。
智通财经 · 05-06
Needham:重申Axonics(AXNX.US)持有评级。
Axonics Inc 报告截至三月的季度业绩 - 收益摘要
Reuters · 05-01
Axonics Inc 报告截至三月的季度业绩 - 收益摘要
Axonics Inc 报告截至 12 月的季度业绩 - 收益摘要
Reuters · 02-29
Axonics Inc 报告截至 12 月的季度业绩 - 收益摘要
Axonics Inc 预计每股收益 6 美分 - 财报前瞻
Reuters · 02-26
Axonics Inc 预计每股收益 6 美分 - 财报前瞻
美国研究综述-伯灵顿商店、Carrols 餐厅、Mastec
Reuters · 01-18
美国研究综述-伯灵顿商店、Carrols 餐厅、Mastec
BUZZ-Piper Sandler 认为医疗技术的宏观环境 "积极 "向好
Reuters · 01-16
BUZZ-Piper Sandler 认为医疗技术的宏观环境 "积极 "向好
美国研究综述-Axonics、贝莱德、高露洁-棕榄公司
Reuters · 01-15
美国研究综述-Axonics、贝莱德、高露洁-棕榄公司
美国研究综述-Axonics、Mohawk Industries、Outset Medical
Reuters · 01-12
美国研究综述-Axonics、Mohawk Industries、Outset Medical
今日优惠-合并与收购
Reuters · 01-09
今日优惠-合并与收购
投行Baird评出2024年医疗技术首选,看好爱尔康(ALC.US)和Axonics(AXNX.US)
智通财经 · 2023-12-25
投行Baird评出2024年医疗技术首选,看好爱尔康(ALC.US)和Axonics(AXNX.US)
加载更多
公司概况
公司名称:
Axonics Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Axonics, Inc.于2012年3月2日在特拉华州注册成立。该公司是一家全球性医疗技术公司,正在为患有膀胱和肠道功能障碍的成年人开发和商业化新产品,包括:(i)用于治疗尿急失禁(UUI)和尿急频率(UUF)的可植入SNM系统,统称为膀胱过度活动症(OAB)、大便失禁(FI)和非梗阻性尿滞留(UR);(ii)用于治疗女性压力性尿失禁(SUI)的尿道填充剂(Bulkamin)。
发行价格:
--
{"stockData":{"symbol":"AXNX","market":"US","secType":"STK","nameCN":"Axonics Inc.","latestPrice":67.71,"timestamp":1715800897167,"preClose":67.45,"halted":0,"volume":163978,"delay":0,"floatShares":50443897,"shares":51018478,"eps":-0.321167,"marketStatus":"交易中","marketStatusCode":2,"change":0.26,"latestTime":"05-15 15:21:41 EDT","open":67.75,"high":67.75,"low":67.4,"amount":11095906.868988,"amplitude":0.005189,"askPrice":67.72,"askSize":356,"bidPrice":67.7,"bidSize":80,"shortable":3,"etf":0,"ttmEps":-0.321167,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1715803200000},"adr":0,"listingDate":1540958400000,"adjPreClose":67.45,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":67.45,"preClose":67.45,"latestTime":"16:01 EDT","volume":7256,"amount":489417.2,"timestamp":1715716892313},"volumeRatio":0.537352},"requestUrl":"/m/hq/s/AXNX","defaultTab":"news","newsList":[{"id":"2433472434","title":"Needham:重申Axonics(AXNX.US)持有评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2433472434","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2433472434?lang=zh_cn&edition=full","pubTime":"2024-05-06 22:15","pubTimestamp":1715004930,"startTime":"0","endTime":"0","summary":"Needham:重申Axonics(AXNX.US)持有评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050622153387d8b83e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050622153387d8b83e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432534663","title":"Axonics Inc 报告截至三月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2432534663","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432534663?lang=zh_cn&edition=full","pubTime":"2024-05-01 05:49","pubTimestamp":1714513796,"startTime":"0","endTime":"0","summary":" * Axonics Inc 报告,在截至三月份的季度调整后每股亏损27美分,低于去年同期的每股收益-19美分。12位分析师对该季度的平均预期是每股亏损8美分。华尔街预期为每股-14美分至-5美分。* Axonics 公司公布的本季度每股收益为亏损 38 美分。* 该公司当季亏损 1911 万美元。* Axonics Inc本季度股价下跌了3.0%,今年迄今为止上涨了7.6%。4月30日 - 预测变化 * 过去三个月,分析师的平均盈利预期下降了约 24.9%。华尔街对 Axonics Inc 的 12 个月目标价中位数为 71.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2415580519","title":"Axonics Inc 报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2415580519","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2415580519?lang=zh_cn&edition=full","pubTime":"2024-02-29 07:27","pubTimestamp":1709162836,"startTime":"0","endTime":"0","summary":" * Axonics Inc 公布的截至12月底的季度调整后每股收益为13美分,高于去年同期的每股收益1美分。13 位分析师对该季度的平均预期是每股收益 6 美分。华尔街预期为每股收益-2 美分至 12 美分。* 营收同比增长 27.7%,达到 1.0974 亿美元;分析师预期为 1.0733 亿美元。* Axonics 公司公布的本季度每股收益为 13 美分。* 公司报告的季度净收入为 657 万美元。* Axonics Inc 的股价本季度上涨了 9.8%。* 华尔街对 Axonics Inc 的 12 个月目标价中位数为 71.00 美元。本摘要由 LSEG 2 月 28 日 11:26 p.m. UTC 数据机器生成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414265002","title":"Axonics Inc 预计每股收益 6 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2414265002","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414265002?lang=zh_cn&edition=full","pubTime":"2024-02-26 19:02","pubTimestamp":1708945334,"startTime":"0","endTime":"0","summary":" * Axonics公司 预计将在2月28日公布截至2023年12月31日的业绩报告。该公司在2024年1月8日发布的截至12月31日的业绩指引显示,营收将在1.093亿美元至1.097亿美元之间。* LSEG 的分析师平均预期 Axonics Inc 每股收益为 6 美分。* 华尔街对 Axonics Inc 的 12 个月目标价中位数为 71.00 美元,高于上一交易日的收盘价 68.39 美元。以前的季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2404360394","title":"美国研究综述-伯灵顿商店、Carrols 餐厅、Mastec","url":"https://stock-news.laohu8.com/highlight/detail?id=2404360394","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2404360394?lang=zh_cn&edition=full","pubTime":"2024-01-18 02:52","pubTimestamp":1705517520,"startTime":"0","endTime":"0","summary":" 路透1月17日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价,其中包括伯灵顿百货公司、Carrols Restaurant Group 和 Mastec。要点 * Ambrx Biopharma Cayman Inc :贝雅将其评级下调至中性 * Burlington Stores Inc :Piper Sandler将其评级从中性上调至增持 * Carrols Restaurant Group Inc :Stephens将其评级从 \"增持 \"下调至 \"等权重\"。* Mastec Inc :贝尔德将其评级从 \"跑赢大盘 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2403896719","title":"BUZZ-Piper Sandler 认为医疗技术的宏观环境 \"积极 \"向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2403896719","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2403896719?lang=zh_cn&edition=full","pubTime":"2024-01-16 23:50","pubTimestamp":1705420221,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 1月16日 - ** 券商Piper Sandler上调了多家医疗科技公司的目标价,包括波士顿科学 、泰莱福克斯 和史赛克 。 ** 表示推荐Alphatec Holdings 和DexCom ,其中DexCom是其今年最看好的公司** 我们预计美国的政治背景会引起一些担忧,但无论谁赢得总统大选,医疗技术都不会受到压力。** 该经纪公司认为,GLP-1 药物对医疗技术的风险很小** 补充说,波士顿科学公司收购 Axonics 是该行业的积极催化剂** 2023年,ATEC上涨22.4%,DXCM上涨9.6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2403065801","title":"美国研究综述-Axonics、贝莱德、高露洁-棕榄公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2403065801","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2403065801?lang=zh_cn&edition=full","pubTime":"2024-01-15 15:16","pubTimestamp":1705302961,"startTime":"0","endTime":"0","summary":" 路透1月15日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价,其中包括 Axonics、贝莱德和高露洁-棕榄公司。* Axonics Inc :Truist Securities将其评级从 \"买入 \"下调至 \"持有\";将目标价从73美元下调至71美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2402293624","title":"美国研究综述-Axonics、Mohawk Industries、Outset Medical","url":"https://stock-news.laohu8.com/highlight/detail?id=2402293624","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2402293624?lang=zh_cn&edition=full","pubTime":"2024-01-12 15:37","pubTimestamp":1705045069,"startTime":"0","endTime":"0","summary":" 路透1月12日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价,其中包括 Axonics、Mohawk Industries 和 Outset Medical。要闻 * Axonics Inc :Leerink Partners将其评级从 \"跑赢大盘 \"下调至 \"市场表现\"。* Mohawk Industries Inc :加拿大皇家银行将其评级从 \"跑输大市 \"上调至 \"行业表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2402617809","title":"今日优惠-合并与收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2402617809","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2402617809?lang=zh_cn&edition=full","pubTime":"2024-01-09 00:58","pubTimestamp":1704733095,"startTime":"0","endTime":"0","summary":" 路透1月8日 - 截至格林尼治标准时间周一16时50分,报道了以下竞购、兼并、收购和处置: ** 强生 称,已同意以20亿美元收购药物开发商Ambrx Biopharma ,以获得属于一类靶向癌症疗法的药物,该疗法已引起其他制药商的兴趣。** 默克公司 表示,它将以约6.8亿美元的价格收购癌症药物开发商Harpoon Therapeutics ,用免疫疗法加强其肿瘤学产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2394382542","title":"投行Baird评出2024年医疗技术首选,看好爱尔康(ALC.US)和Axonics(AXNX.US)","url":"https://stock-news.laohu8.com/highlight/detail?id=2394382542","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2394382542?lang=zh_cn&edition=full","pubTime":"2023-12-25 08:00","pubTimestamp":1703462428,"startTime":"0","endTime":"0","summary":"投行Baird评出2024年医疗技术首选,看好爱尔康和Axonics智通财经APP获悉,投行Baird选择爱尔康、史赛克、库珀医疗、Axonics和波士顿科学作为其2024年的首选医疗科技股。出于类似的原因,Baird也看好隐形眼镜制造商库柏,但相比库柏外科,Baird更看好爱尔康的外科。Baird认为,爱尔康2024年的利润率扩张幅度将大于库珀。Baird表示,Inspire Medical Systems和Intuitive Surgical因估值和“近期潜在负面新闻风险”落选其首选名单。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1044774.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.axonics.com","stockEarnings":[{"period":"1week","weight":0.001},{"period":"1month","weight":-0.0022},{"period":"3month","weight":-0.0052},{"period":"6month","weight":0.1829},{"period":"1year","weight":0.2486},{"period":"ytd","weight":0.0839}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0244},{"period":"3month","weight":0.0496},{"period":"6month","weight":0.1623},{"period":"1year","weight":0.267},{"period":"ytd","weight":0.101}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Axonics, Inc.于2012年3月2日在特拉华州注册成立。该公司是一家全球性医疗技术公司,正在为患有膀胱和肠道功能障碍的成年人开发和商业化新产品,包括:(i)用于治疗尿急失禁(UUI)和尿急频率(UUF)的可植入SNM系统,统称为膀胱过度活动症(OAB)、大便失禁(FI)和非梗阻性尿滞留(UR);(ii)用于治疗女性压力性尿失禁(SUI)的尿道填充剂(Bulkamin)。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.005129},{"month":2,"riseRate":0.666667,"avgChangeRate":0.137752},{"month":3,"riseRate":0.666667,"avgChangeRate":0.009976},{"month":4,"riseRate":0.5,"avgChangeRate":0.001324},{"month":5,"riseRate":0.5,"avgChangeRate":0.083697},{"month":6,"riseRate":0.8,"avgChangeRate":0.09596},{"month":7,"riseRate":0.8,"avgChangeRate":0.102944},{"month":8,"riseRate":0.4,"avgChangeRate":0.01411},{"month":9,"riseRate":0.2,"avgChangeRate":-0.03213},{"month":10,"riseRate":0.4,"avgChangeRate":-0.017059},{"month":11,"riseRate":0.166667,"avgChangeRate":-0.07079},{"month":12,"riseRate":0.833333,"avgChangeRate":0.078665}],"exchange":"NASDAQ","name":"Axonics Inc.","nameEN":"Axonics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Axonics Inc.(AXNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Axonics Inc.(AXNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Axonics Inc.,AXNX,Axonics Inc.股票,Axonics Inc.股票老虎,Axonics Inc.股票老虎国际,Axonics Inc.行情,Axonics Inc.股票行情,Axonics Inc.股价,Axonics Inc.股市,Axonics Inc.股票价格,Axonics Inc.股票交易,Axonics Inc.股票购买,Axonics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Axonics Inc.(AXNX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Axonics Inc.(AXNX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}